Edison, NJ, United States of America

Alfred A Hagedorn, Iii


Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1985-1993

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Inventor Alfred A. Hagedorn, III: A Pioneer in Cardiovascular Pharmaceutical Innovations

Introduction

Alfred A. Hagedorn, III, based in Edison, NJ, has made significant contributions to the field of pharmaceuticals, holding a total of five patents. His work primarily focuses on the development of novel cardiovascular agents that hold the potential to significantly impact heart disease treatment.

Latest Patents

Among his latest patents, Hagedorn has developed innovative compounds such as imidazolylbenzoyl substituted heterocycles. These compounds are presented as cardiovascular agents, specifically as Class III antiarrhythmic agents. The patent details not only the novel compounds but also pharmaceutical formulations containing these compounds, highlighting their potential use in therapeutic applications. Additionally, he has disclosed orally active prodrug derivatives of the cardiotonic agent known as 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one. This patent also discusses various pharmaceutical formulations containing these innovative compounds.

Career Highlights

Alfred A. Hagedorn, III has worked with notable companies in the pharmaceutical industry, including Schering Aktiengesellschaft and Berlex Laboratories, Inc. His experiences at these firms have equipped him with a robust foundation in drug development and innovation.

Collaborations

Throughout his career, Hagedorn has collaborated with esteemed professionals such as Paul W. Erhardt and John W. Lampe. These partnerships have likely contributed to his success in advancing pharmaceutical innovations, showcasing the importance of collaboration in the field of invention.

Conclusion

Alfred A. Hagedorn, III exemplifies the role of inventors in the pharmaceutical industry through his commitment to developing new cardiovascular agents. His contributions, alongside fruitful collaborations and a strong career background, underline the significance of innovation in medical science. Through his patents, Hagedorn continues to impact the treatment landscape for cardiovascular diseases, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…